Spectral Medical Inc
TSX:EDT

Watchlist Manager
Spectral Medical Inc Logo
Spectral Medical Inc
TSX:EDT
Watchlist
Price: 0.485 CAD 2.11% Market Closed
Market Cap: 137.2m CAD
Have any thoughts about
Spectral Medical Inc?
Write Note

Spectral Medical Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Spectral Medical Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Spectral Medical Inc
TSX:EDT
Cash from Financing Activities
CA$9.1m
CAGR 3-Years
-9%
CAGR 5-Years
240%
CAGR 10-Years
-4%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Cash from Financing Activities
CA$2.2m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Cash from Financing Activities
$20.3m
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ESSA Pharma Inc
NASDAQ:EPIX
Cash from Financing Activities
$925.5k
CAGR 3-Years
-81%
CAGR 5-Years
-55%
CAGR 10-Years
-17%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Cash from Financing Activities
-$31.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Covalon Technologies Ltd
XTSX:COV
Cash from Financing Activities
-CA$632.5k
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Spectral Medical Inc
Glance View

Market Cap
137.2m CAD
Industry
Biotechnology

Spectral Medical, Inc. engages in the development and commercialization of therapeutic treatment for septic shock. The company is headquartered in Toronto, Ontario and currently employs 31 full-time employees. The firm has conducted a Phase III clinical trial for its lead product, PMX (Toraymyxin PMX-20R), which is for the treatment of patients with septic shock and endotoxemia that is measured by the Company’s Endotoxin Activity Assay (EAA). EAA and PMX are both Health Canada licensed and commercially available in Canada. The firm through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market.

EDT Intrinsic Value
0.038 CAD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Spectral Medical Inc's Cash from Financing Activities?
Cash from Financing Activities
9.1m CAD

Based on the financial report for Sep 30, 2024, Spectral Medical Inc's Cash from Financing Activities amounts to 9.1m CAD.

What is Spectral Medical Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-4%

Over the last year, the Cash from Financing Activities growth was -40%. The average annual Cash from Financing Activities growth rates for Spectral Medical Inc have been -9% over the past three years , 240% over the past five years , and -4% over the past ten years .

Back to Top